Mixed Topline Phase 3 Results for PDE5 Inhibitor in Early AD

Mixed Topline Phase 3 Results for PDE5 Inhibitor in Early AD

An investigational oral phosphodiesterase-5 (PDE5) inhibitor for Alzheimer’s disease (AD) showed promising but mixed topline results in the phase 3 POLARIS-AD trial.At 52 weeks, once-daily treatment with AR1001 (mirodenafil) was associated with a significant 31% slowing of clinical decline in the monotherapy population of patients not taking standard symptomatic AD medications. In the overall study population, however, clinical decline was slowed by a nonsignificant 7%.The findings were presented on November 16 at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference by principal investigator Sharon J. Sha, MD, MS, chief of the Memory Disorders Division at Stanford University in Stanford, California.Monotherapy BenefitsAR1001 (AriBio Co., Ltd.) enhances cyclic guanosine monophosphate (cGMP) signaling, which preclinical studies suggest may help protect neurons by reducing tau phosphorylation and neuroinflammation and improving neurovascular function.In POLARIS-AD, 1535 patients with biomarker-confirmed mild cognitive impairment or mild dementia due to AD were randomly assigned to receive AR1001 30 mg once daily (n = 769) or placebo (n = 766) for 52 weeks.The primary endpoint was change from baseline to week 52 on the Clinical Dementia Rating-Sum of Boxes (CDR-SB), assessed in two prespecified populations: the overall population and a monotherapy population of 604 patients not receiving acetylcholinesterase inhibitors or memantine at baseline.In the monotherapy population, AR1001 significantly slowed worsening on the CDR-SB compared with placebo (adjusted mean difference, -0.44 points; P = .0266), representing a 31% slowing of clinical decline. In contrast, the treatment difference in the overall population was -0.11 points (P = .4015), representing a nonsignificant 7% slowing of decline.Sha also presented a post hoc analysis of “time saved” on the CDR-SB at week 52, estimating 3.5 months in the monotherapy population compared with 0.8 months in the overall population. The estimates were based on modeled disease trajectories rather than directly observed delays in progression.Secondary Outcomes and BiomarkersSecondary cognitive and functional outcomes generally favored AR1001, particularly in the monotherapy population, although most differences did not reach statistical significance.At week 52, the monotherapy group showed a 1.16-point advantage over placebo on the Alzheimer’s Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog 13; P = .0798). There was also a nominally significant 0.7-point treatment difference on the Mini-Mental State Examination (P = .0232), representing a 28% slowing of decline. The Amsterdam Instrumental Activities of Daily Living Questionnaire also numerically favored AR1001, although the difference was not statistically significant.AR1001 increased cerebrospinal fluid cGMP concentrations compared with placebo in both populations, consistent with its proposed mechanism of action and supporting “target engagement,” Sha noted.Safety and Next StepsAR1001 was generally well tolerated over 52 weeks. Treatment-emergent adverse events occurred in 69.0% of AR1001 recipients and 66.4% of placebo recipients. The most common adverse events with AR1001 included diarrhea, falls, and dizziness.Serious adverse events occurred at similar rates (10% vs 9.8%), but adverse events led to drug discontinuation more frequently with AR1001 (5.2% vs 1.7%). Fatal adverse events occurred in four patients (0.5%) receiving AR1001 and two (0.3%) receiving placebo.Overall, 88% of participants completed the 52-week double-blind treatment period, and about 95% of completers entered the optional 1-year open-label extension, in which all participants received AR1001.AriBio plans to present additional analyses at upcoming scientific meetings and discuss the findings with the FDA to determine next steps. The ongoing open-label extension is expected to conclude in the third quarter of 2027.Promising, but Questions RemainRobert Rissman, PhD, professor of physiology and neuroscience at the University of Southern California, Los Angeles, who wasn’t involved in the study, said the results are promising, calling the potential to improve brain blood flow and enhance amyloid clearance “an attractive concept.”However, the lack of a significant benefit in the overall study population “raises some concern about the generalizability of the treatment when looking at a less select group,” Rissman told Medscape Medical News.Because symptomatic AD medications are widely used, demonstrating benefit only in patients not taking these drugs “represents a significant drawback,” he added.Still, Rissman noted that disease-modifying AD treatments have generally shown the greatest benefits earlier in the disease process, so “it’s possible that they have the right population.”Laura Nisenbaum, PhD, interim chief science officer at the Alzheimer’s Drug Discovery Foundation, found the results “intriguing,” particularly given the drug’s novel mechanism of action.Nisenbaum noted that the monotherapy population was prespecified because investigators had seen a similar signal in phase 2. Still, “the open question is why, and so I think that’s what the field is trying to understand,” she told Medscape Medical News.AriBio funded the study. Sha reported research salary support from AriBio and other pharmaceutical companies, advisory board membership with Cognition Therapeutics, and consulting relationships with Guidepoint Global and ExpertConnect. Rissman reported receiving research support from the National Institute on Aging, Eisai, and the Alzheimer’s Association and having consulting and advisory relationships with multiple pharmaceutical and biotechnology companies, including Biogen, Eisai, Alzheon, DiamiR, and Ionis. Nisenbaum had no relevant disclosures.

Original Source

Read the full article at Medscape →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.